GlucoTrack (GCTK) has provided an announcement.
Glucotrack, Inc. recently announced the successful completion of the initial 30 days in a 60-day preclinical study for a groundbreaking epidural glucose monitoring system. This marks a significant milestone for the company, potentially revolutionizing glucose monitoring for patients. The announcement underlines the company’s commitment to innovation in healthcare and could have implications for investors and stakeholders monitoring Glucotrack’s progress in the medical technology sector.
See more data about GCTK stock on TipRanks’ Stock Analysis page.
